Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy acquires Biovel vaccine business

India's largest pharmaceutical company, Ranbaxy, has announced it is to acquire the product rights and manufacturing facility of Biovel Lifesciences

India's largest pharmaceutical company, Ranbaxy, has announced it is to acquire the product rights and manufacturing facility of Biovel Lifesciences. The value of the deal was not disclosed.

The transaction will provide Ranbaxy with access to all of Biovel's products (including the Typhoid Vi antigen and Hib conjugate vaccines, for which Biovel has received regulatory approval for India), intellectual property and its pipeline, along with a manufacturing facility in Bangalore, India.

Ranbaxy's CEO and MD, Atul Sobti, said: "With an increasing focus on prevention of disease, the importance of the vaccine market has never been greater. This transaction with Biovel provides us an entry platform to manufacture vaccines as well as biotherapeutics. The vaccine and biotherapeutics business will be an important part of our growth strategy."

According to Ranbaxy, the Indian vaccine market is growing at 10 per cent per annum – 1 per cent higher than the global rate. The global vaccines market is predicted to reach $34bn by 2014.

20th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics